Article | June 11, 2024

Effectively Enabling Rare Diseases To Reach Patients

By Dr. Rebecca Abram, Director, Strategic Technical Marketing, and Dr. Joanna Norman, Director of PD Operations, Viral Gene Therapy Operations, U.K.

GettyImages-1408798973 patient centricity nurse doctor

Rare diseases, a widespread, unmet medical challenge affecting over 400 million people globally, are no longer an insurmountable hurdle. While there are over 7,000 rare diseases affecting patients, recent advancements offer a glimmer of hope, including five groundbreaking approvals for cell, gene, and RNA therapies. The increasing number of fast-track approvals and orphan drug designations from regulatory authorities signifies a commitment to accelerating the development of rare disease treatments.

However, to bring a rare disease therapy to clinic, developers will need a robust understanding of how to manage timeline, budget, critical quality attributes, and scale-up. In many cases, inexperienced sponsors are facing clinical holds from the FDA as a result of insufficient chemistry, manufacturing, and controls information. To alleviate this, developers could consider partnering early with an experienced CDMO that offers flexibility and capacity at multiple scales, regulatory knowledge, and high-throughput analytical processing technologies. Download the full article to learn more about what a manufacturing partner can offer your rare disease therapy.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Outsourced Pharma

FUJIFILM Diosynth Biotechnologies